Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17559133 | 0.93 | KAT2B (0.49) | KAT2BSMN1; SMN2TBXAS1GAAPARG | |
| SCHEMBL30976426 | 0.79 | TBXAS1 (0.51) | KAT2BTBXAS1ADRA1AHRH1ADRA1B | |
| SCHEMBL17559135 | 0.78 | KAT2B (0.50) | KAT2BSMN1; SMN2TBXAS1PARGHPGD | |
| SCHEMBL31091769 | 0.78 | KAT2B (0.50) | KAT2BSMN1; SMN2TBXAS1PARGHPGD | |
| SCHEMBL29078201 | 0.77 | KDM4C (0.39) | GAA | |
| SCHEMBL30976435 | 0.74 | SMN1; SMN2 (0.49) | KAT2BSMN1; SMN2GAAHPGDMAPK1 | |
| SCHEMBL19770700 | 0.72 | PARG (0.45) | KAT2BSMN1; SMN2PARGHPGD | |
| SCHEMBL16651749 | 0.72 | BRD4 (0.45) | — | |
| SCHEMBL30976391 | 0.72 | TBXAS1 (0.48) | KAT2BTBXAS1GAAADRA1AHRH1 | |
| SCHEMBL30976386 | 0.72 | KAT2B (0.46) | KAT2BSMN1; SMN2TBXAS1GAAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | SOLEY THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4619387-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240374589-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024108131-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-10155764-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC (US) | 2018-12-18 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3189049-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016036954-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016036954-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | MKI67, BCL2, CCAR2 | KAT2B 112/4885SMN1; SMN2 1302/4885TBXAS1 2241/4885 |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | NCOR1, NOP56, NCOR2 | KAT2B 388/4885SMN1; SMN2 696/4885TBXAS1 3362/4885 |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | KAT2B 41/4885SMN1; SMN2 520/4885TBXAS1 2786/4885 |
| US-10155764-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC1 | KAT2B 41/4885SMN1; SMN2 520/4885TBXAS1 2786/4885 |
| US-20240374589-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | MKI67, HDAC6, BCL2 | KAT2B 263/4885SMN1; SMN2 1973/4885TBXAS1 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.